Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology

Department

Allergy and Immunology

Document Type

Article

Publication Title

Critical Reviews in Oncology/Hematology

Abstract

Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a common condition that presents with recurrent infection. SID is due to both the inherent immune defects due to the malignancy, as well as secondary to cancer therapies, many of which have B-cell depleting properties. The early diagnosis of SID and the optimization of intervention strategies are key to delivering the most effective cancer treatments and reducing infection-related morbidity and mortality. This review discusses current practice, recommendations, and challenges for SID diagnosis, based on the evaluation of clinical history and laboratory assessments, and the effectiveness of specific vaccines and immunoglobulin replacement therapy in reducing the frequency and recurrence of infections in patients with SID, and the healthcare system-associated costs.

First Page

103896

DOI

10.1016/j.critrevonc.2022.103896

Volume

181

Publication Date

1-1-2023

Medical Subject Headings

Humans; Immunoglobulins, Intravenous (therapeutic use); Immunologic Deficiency Syndromes; Hematologic Neoplasms (complications, epidemiology, therapy); Neoplasms (drug therapy)

PubMed ID

36528276

Link to Full Text

Share

COinS